Transgene SA (TRGNF)
OTCMKTS · Delayed Price · Currency is USD
1.000
0.00 (0.00%)
Feb 5, 2026, 4:00 PM EST
Transgene Market Cap
Transgene has a market cap or net worth of $273.6 million as of February 12, 2026. Its market cap has increased by 187.86% in one year.
Market Cap
273.60M
Enterprise Value
290.56M
Revenue
8.90M
Ranking
n/a
PE Ratio
n/a
Stock Price
$1.00
Market Cap Chart
Since March 30, 1998, Transgene's market cap has increased from 164.41M to 273.60M, an increase of 66.41%. That is a compound annual growth rate of 1.84%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 11, 2026 | 267.07M | -13.47% |
| Dec 31, 2025 | 308.65M | 232.16% |
| Dec 31, 2024 | 92.92M | -38.98% |
| Dec 29, 2023 | 152.29M | -13.51% |
| Dec 30, 2022 | 176.08M | -37.53% |
| Dec 31, 2021 | 281.86M | 67.10% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Northwest Biotherapeutics | 411.40M |
| CytoDyn | 311.51M |
| Silence Therapeutics | 211.61M |
| Vaxart | 141.56M |
| HST Global | 139.70M |
| BioStem Technologies | 92.40M |
| Nuo Therapeutics | 76.77M |
| VitaSpring Biomedical | 51.78M |